ReN 001

Drug Profile

ReN 001

Alternative Names: CTX 0E03 neural stem cells; ReN-001

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReNeuron
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 14 Dec 2017 US FDA approves IND application for ReN 001 in Stroke
  • 14 Dec 2017 ReNeuron plans to initiate the phase IIb PISCES-III trial for Stroke in the US in 1H 2018
  • 22 Nov 2017 Phase-I development for Stroke (In the elderly) is ongoing in Scotland (Intracerebral, Implant) (ReNeuron Pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top